Microvascular disease is an important cause of morbidity in diabetes. There is evidence that impaired autoregulation of blood flow is involved in the pathogenesis of diabetic microangiopathy. The vascular endothelium plays a central role in the regulation of vascular tone. Endothelin (ET)-l is a potent endothelium-derived vasoconstrictor substance that contributes to basal vascular tone. Impaired vasoconstriction in response to endogenous ET could result in hyperperfusion and subsequent microvascular damage. The purpose of our study was to determine whether vascular responses to locally administered ET-1 are impaired in NIDDM. Nine patients with NIDDM and 12 control subjects underwent cannulation of the nondominant brachial artery. Forearm blood flow (FBF) was measured at baseline and during the drug infusion using strain-gauge venous occlusion plethysmography. ET-1 (5 pmol/min) was infused for 60 min at a rate of 1 ml/min. FBF was measured during the first 5 min of the infusion and at 5-min intervals thereafter. Results were expressed as change in FBF from baseline (ml • 100 ml" 1 • min" 1 ) and were analyzed using repeated measures analysis of variance and Dunnett's test of multiple comparisons. Control subjects showed a gradual onset of vasoconstriction in response to ET-1, which reached maximum at 35 min (1.1 ml • 100 ml" 1 • min" 1 ; P < 0.01). There was no reduction in FBF in response to ET-1 in the diabetic group. The differences between the diabetic and control groups were significant (P < 0.03). In conclusion, ET-1 infused locally at 5 pmol/min does not cause vasoconstriction in patients with NIDDM. Diabetes 45:105-107, 1996 M icrovascular disease is an important cause of morbidity and mortality in both IDDM and NIDDM. It can result in retinopathy and nephropathy, and it contributes to foot pathology, diabetic cardiopathy, and neuropathy. Despite this, the pathogenesis of diabetic microangiopathy is uncertain. The hemodynamic hypothesis argues that an early increase in precapillary blood flow and capillary hypertension precede the adaptive changes that lead to microvascular sclerosis (1-3). Although the majority of evidence for the hemodynamic hypothesis relates to IDDM, increased renal plasma flow and impaired maximum vasodilatation to thermal injury have been described in patients with NIDDM (4,5). These findings indicate that autoregulation of blood flow is disturbed in this group also. The vascular endothelium plays a central role in the regulation of vascular tone through the production of several vasoactive substances, including endothelin (ET)-l, nitric oxide, and cyclooxygenase products. Previous studies in this department have demonstrated impaired endothelium-dependent vasodilatation in patients with NIDDM, probably due to impaired release of nitric oxide or increased production of a cyclooxygenase-derived constrictor substance (6). ET-1 was first discovered in 1988 in the supernatant of aortic endothelial cells (7). It is a 21-amino acid peptide formed by proteolytic cleavage of its precursor, big-ET. The local vascular effects of ET-1 have been determined in healthy subjects (8,9). The potent and prolonged vasoconstrictor effects of ET-1 are mediated by ET A and ET B receptors on the vascular smooth muscle and are opposed by ET B receptors on the endothelium. In vitro studies of streptozotocin-induced diabetic rats have demonstrated reduced maximum vasoconstrictor responses to ET-1 (10). The mechanisms involved in these findings are uncertain but appear to be endothelium-independent. The purpose of the present study was to determine whether forearm vascular responses to ET-1 are impaired in patients with NIDDM. This is the first reported in vivo study in humans of the effects of ET-1 on vascular tone in diabetes.
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The vascular endothelium plays a central role in the regulation of vascular tone through the production of several vasoactive substances, including endothelin (ET)-l, nitric oxide, and cyclooxygenase products. Previous studies in this department have demonstrated impaired endothelium-dependent vasodilatation in patients with NIDDM, probably due to impaired release of nitric oxide or increased production of a cyclooxygenase-derived constrictor substance (6) . ET-1 was first discovered in 1988 in the supernatant of aortic endothelial cells (7) . It is a 21-amino acid peptide formed by proteolytic cleavage of its precursor, big-ET. The local vascular effects of ET-1 have been determined in healthy subjects (8, 9) . The potent and prolonged vasoconstrictor effects of ET-1 are mediated by ET A and ET B receptors on the vascular smooth muscle and are opposed by ET B receptors on the endothelium. In vitro studies of streptozotocin-induced diabetic rats have demonstrated reduced maximum vasoconstrictor responses to ET-1 (10) . The mechanisms involved in these findings are uncertain but appear to be endothelium-independent. The purpose of the present study was to determine whether forearm vascular responses to ET-1 are impaired in patients with NIDDM. This is the first reported in vivo study in humans of the effects of ET-1 on vascular tone in diabetes.
RESEARCH DESIGN AND METHODS
Nine patients with NIDDM (seven men, two women) of mean age 55 years (range 45-64) were recruited. The mean known duration of diabetes was 4.9 years (range 1-10). Diabetic control was achieved by diet alone or diet and sulfonylurea and/or biguanide preparation. Subjects were excluded if they had a history of cardiovascular disease, hypercholesterolemia, hypertension (blood pressure > 160/90), renal impairment (glomerular filtration rate <60 ml/min), or cigarette smoking or if they were taking any cardiovascular drugs. A total of 12 healthy volunteers (8 men, 4 women), mean age 54 years (range 49-64), were recruited to act as a control group (Table 1 ). All subjects underwent a full history and medical examination. The diabetic subjects also underwent funduscopy, assessment of vibration perception at each great toe and medial malleolus, ankle-to-brachial Doppler ratios, measurement of timed overnight urinary albumin excretion and of creatinine clearance, and measurement of heart rate variability by electrocardiography during deep breathing to assess cardiac autonomic function. All subjects gave written informed consent for all procedures. The study was approved by the local ethics committee of the Queens University of Belfast. Data are mean (95% CI) or n.
All subjects fasted for 10 h before the study. Alcohol and caffeinecontaining beverages were prohibited during this time. The studies took place in a temperature-controlled room (24-26°C) with the subject supine and the experimental arm resting on a support slightly above the level of the heart. A 20-gauge polyethylene cannula (Vygon leader cath, Ecouen, France) was inserted into the nondominant brachial artery under local anesthesia (1% lignocaine, Antigen Pharmaceuticals, Roscrea, Ireland). After a period of at least 30 min, resting forearm blood flow (FBF) was measured by venous occlusion plethysmography. An indium-gallium strain gauge coupled to an electronically calibrated plethysmograph (Medasonics model SPG 16, Mountain View, CA) was connected to a two-channel chart recorder (Medasonics model R12B) to record FBF. The hand was excluded from the circulation by a wrist cuff inflated to 200 mmHg for 30 s before and during blood flow measurements. An upper-arm cuff was inflated to 40 mmHg for 5-10 s to achieve venous occlusion. The average of five consecutive measurements was used for statistical analysis. An arterial blood sample was taken from the cannula for measurement of fasting serum insulin (Abbott, North Chicago, IL) by enzyme immunoassay and plasma ET-1 (Nichols Institute, Wijchen, The Netherlands) by radioimmunoassay.
Using a constant-rate infusor (Braun Perfusor pump, Melsungen, Germany), ET-1 (Clinalfa, Laufelfingen, Switzerland) was infused into the arterial cannula at 5 pmol/ml at a rate of 1 ml/min for 60 min. FBF was measured during the first 5 min of infusion and at 5-min intervals thereafter until completion of the drug infusion. Measurements were continued at 10-min intervals after the infusion for a further 60 min.
Serum insulin and plasma ET-1 concentrations were compared using independent t tests. Vascular responses to infused ET-1 are expressed as change in FBF from baseline (ml -100 ml" 1 • min" 1 ). They were analyzed using repeated measures analysis of variance for group differences and Dunnett's test of multiple comparisons for dose effects within each group.
RESULTS
Clinical and biochemical characteristics of the diabetic and control groups were similar, apart from fasting blood glucose, which was significantly higher in the diabetic group (P < 0.01) ( Table 1) . No significant differences were found in age, BMI, blood pressure, serum creatinine, total cholesterol, or baseline FBF (P > 0.05). Two of the diabetic subjects had evidence of impaired peripheral vibration sensation, and two had reduced heart rate variability, indicating peripheral and autonomic neuropathy, respectively. None had evidence of retinopathy, nephropathy, or peripheral vascular disease. There were no significant differences in plasma ET-1 or serum insulin concentrations between groups (P > 0.05) ( Table 1) .
Control subjects showed a gradual onset of vasoconstriction in response to ET-1, which reached maximum at 35 min (1.1 ml • 100 ml" 1 • min" 1 ; P < 0.01). There was a small but not significant increase in FBF in response to ET-1 in the diabetic group (P > 0.05) (Fig. 1) . The differences between the diabetic and control groups were significant (P < 0.03).
DISCUSSION
We have demonstrated a lack of vasoconstriction in response to locally infused ET-1 in the forearm vasculature of patients with NIDDM. The dose of ET used has previously been found to be without systemic effects (11) . Our findings therefore reflect local vascular effects rather than reflex or renal responses.
There are several possible explanations for the mechanisms involved in the impaired responsiveness to ET-1 in diabetes. Our findings could be attributable to downregulation of the smooth muscle ET A and ET B receptors, which mediate vasoconstriction, in the diabetic group. This could be due to increased local concentrations of ET-1, despite our findings of normal plasma concentrations, because ET-1 is a paracrine hormone. Insulin has been found to stimulate production and secretion of ET-1 (12). Hyperinsulinemia is not involved in the lack of responsiveness to ET-1 in our A.G. NUGENT AND ASSOCIATES study because the serum insulin concentrations of the diabetic and control groups were similar. Increased concentrations of the precursor of ET-1, big-ET, perhaps caused by decreased ET-converting enzyme activity, could also result in receptor downregulation because big-ET is a weak agonist for ET receptors.
Inactivation of smooth muscle ET A and ET B receptors, perhaps by blockage by a macromolecule such as big-ET, could explain the lack of vasoconstriction in the diabetic group. A recent study of plasma concentrations of ET in congestive heart failure has demonstrated that the elevation of ET in this condition represents principally big-ET (13). It is not known whether this is also the case in diabetes.
Increased production of a vasodilator substance in response to ET-1 in diabetes could oppose the vasoconstrictor effects. Upregulation of the endothelial ET B receptors resulting in increased production of nitric oxide or prostacyclin could mediate these effects. In vitro studies in rats, however, indicate that the impaired vasoconstrictor responses to ET are endothelium-independent (10). Also, previous studies in NIDDM have demonstrated impaired vasodilatation in response to endothelium-dependent vasodilators (6) .
Reduced contractility to ET-1 of bovine pericytes in high concentrations of glucose has been described and does not appear to be related to altered receptor binding (14) . Hyperglycemia may impair intracellular events after receptor binding by ET-1 leading to impaired contraction. A link with hyperglycemia is supported by the finding that an insulininduced decrease in blood glucose concentration reduces retinal blood flow in patients with NIDDM (15) .
Finally, a nonspecific impairment of smooth muscle contraction may occur in diabetes. This explanation is unlikely because previous studies have shown no difference in pressor responses to norepinephrine and ANG-II in diabetes (16) . We have previously measured forearm vascular responses to serotonin in patients with NIDDM and control subjects and have demonstrated no difference in forearm vasoconstrictor responses to high-dose serotonin in diabetic and control groups (17) .
Our finding of normal plasma levels of ET-1 in the diabetic subjects conflicts with previous reports of elevated plasma concentrations of ET-1 in diabetes (18, 19) . This could be due to the lack of detectable macrovascular disease, retinopathy, and nephropathy in our patient group.
Further studies would help to elucidate the mechanisms involved in the impaired responsiveness to ET-1 in diabetes. Measurement of vascular response to higher doses of ET-1 and to specific ET antagonists would help to determine the involvement of receptor downregulation or inactivation. Measurement of plasma concentrations of big-ET would also be useful. The role of increased production of a vasodilator substance could be determined by measurement of vascular response to co-infusion of ET-1 and the nitric oxide synthase inhibitor L-A^-monomethyl-L-arginine and to infusion of ET-1 in the presence of cyclooxygenase inhibition. The involvement of hyperglycemia could be assessed by measurement of vascular response to ET-1 under euglycemic and hyperglycemic conditions using the glucose clamp technique.
In conclusion, we have demonstrated for the first time a lack of responsiveness to ET-1 in NIDDM in vivo. Abnormal regulation of vascular tone by endogenous ET-1 could result in hyperperfusion of the microvasculature and subsequent microvascular damage and supports the hemodynamic hypothesis for diabetic microvascular disease.
